QIAGEN Shares Outstanding 2010-2022 | QGEN

QIAGEN shares outstanding history from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • QIAGEN shares outstanding for the quarter ending September 30, 2022 were 0.230B, a 0.88% decline year-over-year.
  • QIAGEN 2021 shares outstanding were 0.232B, a 0.93% decline from 2020.
  • QIAGEN 2020 shares outstanding were 0.234B, a 3.28% increase from 2019.
  • QIAGEN 2019 shares outstanding were 0.227B, a 2.86% decline from 2018.
QIAGEN Annual Shares Outstanding
(Millions of Shares)
2021 232
2020 234
2019 227
2018 233
2017 233
2016 239
2015 239
2014 243
2013 233
2012 232
2011 230
2010 232
2009 206
QIAGEN Quarterly Shares Outstanding
(Millions of Shares)
2022-09-30 230
2022-06-30 230
2022-03-31 232
2021-12-31 232
2021-09-30 232
2021-06-30 232
2021-03-31 231
2020-12-31 234
2020-09-30 236
2020-06-30 234
2020-03-31 232
2019-12-31 227
2019-09-30 227
2019-06-30 233
2019-03-31 234
2018-12-31 233
2018-09-30 235
2018-06-30 234
2018-03-31 233
2017-12-31 233
2017-09-30 233
2017-06-30 233
2017-03-31 235
2016-12-31 239
2016-09-30 239
2016-06-30 239
2016-03-31 238
2015-12-31 239
2015-09-30 228
2015-06-30 228
2015-03-31 229
2014-12-31 243
2014-09-30 232
2014-06-30 232
2014-03-31 234
2013-12-31 233
2013-09-30 233
2013-06-30 225
2013-03-31 233
2012-12-31 232
2012-09-30 233
2012-06-30 231
2012-03-31 230
2011-12-31 230
2011-09-30 229
2011-06-30 232
2011-03-31 231
2010-12-31 231
2010-09-30 230
2010-06-30 233
2010-03-31 227
2009-12-31 232
2009-09-30 201
2009-06-30 196
2009-03-31 196
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.086B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00